APMD

Apnimed Inc

17.76

Oct 16 • 3:59 PM ET -0.49 (-2.66%)

17.76

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: OLMA CGEM ANRO IVA SVRA JANX REPL LXRX AXSM JAZZ

| Held by: VTI IWM VXF VTWO IWO SCHA IWN IWC VTWG SCHB

Scroll to Statements

Index	RUT
Market Cap	739.36M
Enterprise Value	892.85M
Income	-
Sales	-
Book/sh	-4.23
Cash/sh	4.15
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Jul 31, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	4.28
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.06
Current Ratio	5.06
Debt/Eq	1.15
LT Debt/Eq	1.15
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.64
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-69.75% -
Sales past 3/5Y	237.57% -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Sep 08 AMC
EPS/Sales Surpr.	905.42% -

Insider Own	6.80%
Insider Trans	12.97%
Inst Own	34.98%
Inst Trans	26.79%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-14.07%
SMA50	-29.28%
SMA200	-29.51%
Trades

Shs Outstand	41.63M
Shs Float	38.80M
Short Float	4.55%
Short Ratio	3.27
Short Interest	1.76M
52W High	35.29 -49.67%
52W Low	16.12 10.17%
Volatility	8.25% 11.00%
ATR (14)	2.15
RSI (14)	35.59
Beta	-
Rel Volume	0.44
Avg Volume	539.24K
Volume	235,056

Perf Week	-4.10%
Perf Month	-36.82%
Perf Quarter	-
Perf Half Y	-
Perf YTD	-19.27%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	50.33
Prev Close	18.25
Price	17.76
Change %	-2.66%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-25-26	Initiated	Evercore ISI	Outperform
Aug-25-26	Initiated	Cantor Fitzgerald	Overweight	$60
Aug-25-26	Initiated	BofA Securities	Buy	$41

Oct-12-26 04:05PM	Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026 (GlobeNewswire)
Oct-02-26 04:05PM	Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-22-26 01:39PM	Was Moderna Stock's Cancer Vaccine Run Visible In Advance? (Trefis)
Sep-08-26 04:39PM	Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-04-26 04:01PM	Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
11:13AM	Loading…
Aug-26-26 11:13AM	Moderna Stock Carries A Market Value Its Revenue Does Not Support (Trefis) +8.07%
Aug-25-26 12:12PM	Apnimed shares surge on bullish BofA initiation (Proactive) +6.79%
08:14AM	Nasdaq rises as Wall Street gets relief from falling yields (Proactive)
Aug-24-26 03:01PM	Moderna Stock Had A Readout Waiting In Plain Sight (Trefis) -8.56%
Aug-20-26 02:21PM	Moderna's Melanoma Result Landed On A Market Positioned The Other Way (Trefis) -10.86%
Aug-03-26 04:35PM	Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)

Apnimed, Inc. operates as a clinical-stage company. It engages in the discovery, development, and commercialization of oral therapies for sleep-related breathing diseases. The company was founded by Lawrence G. Miller, Barry Wohl and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA.

CEO & DirectorMr. Kevin Robert Lind

M.P.H.Dr. Lawrence G. Miller M.D.

President & COOMr. Dennis Patrick Molnar M.B.A.

Co-Founder & Chief Scientific OfficerDr. Luigi Taranto Montemurro M.D.

Chief Financial OfficerMr. Michael B. Kelly

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Morningside Venture Investment	10% Owner	Aug 03 '26	Buy	16.00	312,500	5,000,000	7,152,713	Aug 05 04:18 PM
SEKHRI PAUL J	Director	Aug 03 '26	Buy	16.00	12,500	200,000	12,500	Aug 03 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

APMD

Apnimed Inc

Upgrade your Finviz experience